ArticleClinical drug investigation2026
Operationalizing Single-Dose Long-Acting Lipoglycopeptides for Treatment of ABSSSI in a U.S. Community Hospital Emergency Department.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLong-acting lipoglycopeptides (LaLGPs) offer an alternative to standard intravenous (IV) antibiotics for treating acute bacterial skin and skin structure infections (ABSSSIs). In September 2024, Munson Medical Center (Traverse City, MI) implemented an emergency department (ED)-based dalbavancin protocol targeting stable patients with ABSSSI who would otherwise require short-stay hospital admission. This study evaluated the clinical outcomes, operational feasibility, and financial impact of implementing an ED-based LaLGP protocol for ABSSSI management.
methodsThis single-center, quasi-experimental pre-post study was conducted at a community hospital ED in the USA. The pre-implementation group included patients admitted for ≤ 72 h with ABSSSI (July 2022-August 2024). The post-implementation group received 1500 mg of dalbavancin in the ED per protocol (September 2024-May 2025). The primary outcome was 30-day hospital admission for recurrent ABSSSI. Secondary outcomes included 30-day ED visits, new antibiotic prescriptions, and 72-h all-cause admission.
resultsOf 215 patients screened, 67 were included (48 pre-implementation, 19 post-implementation). No significant differences were observed in 30-day recurrent ABSSSI hospitalizations (2.1% versus 10.5%; P = 0.192), ED visits (4.2% versus 10.5%; P = 0.317), new antibiotic prescriptions (27.1% versus 10.5%; P = 0.200), or 72-h all-cause admissions (0% versus 5.3%; P = 0.284). A model-based, assumption-dependent financial analysis estimated that the pathway avoided 36 inpatient days over the 8-month post-implementation period, corresponding to an estimated net positive financial margin of approximately $100,000 USD.
conclusionsAn ED-based LaLGP protocol for ABSSSI management was feasible for selected clinically stable patients. Although some outcomes were numerically higher in the post-implementation group, the small sample size and low event rates limited definitive comparisons.
Indexed as
Identifiers
42525199What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.